Search
Menu
Home
HTB
2009
August
HTB
August 2009
Contents
Editorial
Volume 10 Number 7/8 July/August 2009
Special reports
HIV swine flu triage tools and flowcharts
HIV and swine flu patient leaflet
Conference reports
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town
Five-year survival rates of 87% without routine CD4 or laboratory monitoring in DART study demonstrate an important model for ARV access programmes
Biomarkers associated with mortality: long-term follow up from SMART
Update on Interleukin-2 clinical trials
Influenza vaccine effective in HIV-positive adults
Reducing HIV transmission during breastfeeding
Treating children previously exposed to single dose nevirapine
10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam
Monotherapy study may explain previous poor clinical results when abacavir and tenofovir are used in combination
Interactions between ARVs and antimalarials atovaquone and proguanil
Four weeks lopinavir/r to cover functional monotherapy when stopping HAART
Efavirenz-related studies: genetics, smoking and TDM
Atazanavir: a suitable case for TDM?
Raltegravir PK in blood plasma and the genital tract
A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission
Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding
Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children
Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents
Bioavailability of Thai generic lopinavir/ritonavir
XVIII International Drug Resistance Workshop, 9-13 June 2009, Florida
Transmitted multidrug-resistant HIV persists in PBMC DNA for years
Low-level Q148R in people without integrase inhibitor experience
Cut-offs suggested for predicting efavirenz failure with low-level K103N
Lower M184V rates with FTC/TDF than with 3TC/TDF
HBV resistance to lamivudine at undetectable and low levels of viremia
Antiretrovirals
Raltegravir approved in the US for treatment-naive patients: paranoia and anxiety added as side effects
Guidelines
UK (BHIVA) guidelines online for comment (2009)
TB coinfection
TMC207 reduces time to sputum conversion in phase II trial on patients with drug-resistant TB
Basic science and immunology
Maximum suppression: ART intensification does not reduce residual viral load
The role of Ad5-specific CD4 T-cells in enhancing risk of HIV acquisition in the Merck vaccine trial
Tracing HIV reservoirs
Illuminating early events in HIV infection using single genome amplification
PDFs
Volume 10 Number 7/8 July/August 2009 PDF
HTB RSS
Early access
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
20 December 2024
i-Base guides updated online
5 December 2024
All early access reports
Current issues
December 2024
November 2024
October 2024
Back issues
Special report
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate